Healthcare Specialist, Westhouse Medical Services Plc. (FRA:5WM) today announces it has commenced the process for dual listing on the OTCQX, alongside its present listing on the Frankfurt Stock Exchange (FSE). Soloway Group, a licensed Principal American Liaison, will handle and advise on the OTCQX listing procedure.
The OTCQX application follows Westhouse's application to move its listing from the First Quotation Board of the Frankfurt Stock Exchange to the Open Entry Standard.
Jack Kaye, founder and CEO of Westhouse Medical Services, comments: "The listing on the OTCQX is a strategic move to match the company's recent expansion into the US market. The OTCQX listing, as well as the FSE market upgrade, will allow better access to the US healthcare market, appealing to North American investors.
We believe this will allow us to maintain our commitment to creating value for investors, providers and patients alike by delivering step changes in the effectiveness and quality of primary healthcare provision."
The OTCQX application comes before the planned autumn 2012 launch of BreastCheck - a thermographic, non-invasive breast cancer scanning device, which women of all ages can use to detect abnormalities within the breast tissue.
Westhouse also recently secured a deal for the acquisition of US-listed Sunridge International's patents for PNT, a new glaucoma procedure, which could revolutionise the way glaucoma is treated globally.
WESTHOUSE MEDICAL SERVICES PLC